Clinical Trials on Long QT Syndrome Type 3

Total 12435 results

University of Birmingham
Jazz Pharmaceuticals; Adienne SA; IMPACT (funded by NHS Blood & Transplant, Anthony...

Active, not recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (COSI)

Acute Myeloid Leukaemia | High-risk Myelodysplastic Syndrome

United Kingdom
University of Rochester

Active, not recruiting

A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Daiichi Sankyo, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Grupo Cooperativo de Hemopatías Malignas

Withdrawn

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Mexico
Jonsson Comprehensive Cancer Center

Withdrawn

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia
Aileron Therapeutics, Inc.

Completed

Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Unknown

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myeloid

United States
Dartmouth-Hitchcock Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

United States
Biosuccess Biotech Co., Ltd.

Terminated

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome (AML/MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Hoffmann-La Roche

Completed

A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Shanghai Tong Ren Hospital

Unknown

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Acute Myeloid Leukemia | Myelodysplastic Syndrome

China
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company; Eisai Inc.

Completed

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Sheba Medical Center

Completed

TevaGastrim for Stem Cell Mobilization Sibling Donors

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
University of Pittsburgh

Completed

Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Mirati Therapeutics Inc.

Completed

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States, Canada, Australia
University of Chicago

Completed

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Completed

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase II 5-Azacytidine Plus VPA Plus ATRA

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Heinrich-Heine University, Duesseldorf

Completed

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
European Organisation for Research and Treatment...

Unknown

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Myelodysplastic Syndromes | Leukemia

Switzerland, Netherlands, France, Belgium, Germany, Sweden, Croatia, Czech Republic, Italy
Peking University Third Hospital

Completed

Comparison of Ocular Surface Features in Patients With Diabetes and Dry Eye Syndrome

Diabetes Mellitus Type 2 | Dry Eye Syndrome

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

France, Australia
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Withdrawn

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
Universidad de Magallanes
Teaching Assistance and Research Center of the University of Magallanes CADI-UMAG and other collaborators

Active, not recruiting

Multimodal Long Covid19 (MLongCovid)

Long COVID-19 Syndrome

Chile
Sleepinnov Technology
University Hospital, Grenoble; ICUREsearch

Completed

Obstructive Sleep Apnea Syndrome: Evaluation of the Efficacy of Sleepinnov© (Spiri+) Continuous Positive Airway Pressure Device (Spiri+)

Obstructive Sleep Apnea Syndrome

France
LivaNova
National Research Agency, France

Completed

PErsonalized and Adaptive Kinesthetic stImulation Therapy, Based on Cardio-respiratory Holter moNitoring, for Sleep Apnea syndrOmes (EKINOx)

Obstructive Sleep Apnea Syndrome

France
University Hospital, Montpellier

Completed

Air Leakage Under Continuous Positive Airway Pressure (SAS-leak-1)

Obstructive Sleep Apnea Syndrome

France
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Upper Airway Reeducation in Moderate Obstructive Sleep Apnea Syndrome (SAOSGENIO)

Moderate Obstructive Sleep Apnea Syndrome

France
Karolinska University Hospital

Completed

ATT Compared With ATE in OSAS Children (RCT ATE/ATT)

Obstructive Sleep Apnea Syndrome in Children

Sweden
University of Alabama at Birmingham

Terminated

Prospective Study to Evaluate Outcomes From Transoral BOT Resection for OSAHS

Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)

United States
Sakarya University

Unknown

Evaluation of Prolidase in Obstructive Sleep Apnea Syndrome

Obstructive Sleep-Apnea Syndrome

Turkey
Universidade Nova de Lisboa
Centro Hospitalar Lisboa Norte; Fundação para a Ciência e a Tecnologia; NOVA... and other collaborators

Completed

Identification of Biomarkers for Obstructive Sleep Apnoea Syndrome

Obstructive Sleep Apnoea Syndrome

Portugal
University of Pittsburgh

Withdrawn

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (UPCI 13-165)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Ruhr University of Bochum

Completed

Correlation Between 3 Phase Bone Scintigraphy and Pressure Pain Thresholds in Patients With Complex Regional Pain Syndrome (CRPS)

Healthy Subjects | Complex Regional Pain Syndrome Type I of the Upper Limb | Unilateral Limb Pain of Other Origin

Germany
National Cancer Institute (NCI)

Active, not recruiting

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Juan Pascual

No longer available

Post Study Continuation of C7 for G1D

Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome

United States
Dana-Farber Cancer Institute
National Institutes of Health (NIH); Brigham and Women's Hospital

Completed

Collection and Banking of Leukemia Cells MDS/AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Massachusetts General Hospital

Recruiting

A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center

Active, not recruiting

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia

United States
King's College Hospital NHS Trust

Unknown

Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy (PRO-DLI)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom

Clinical Trials on Long QT Syndrome Type 3

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations